Publications by Sylvie Pollmann
14 publications found
Original articles
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
Oncoimmunology, 10 (1), 1936757
DOI 10.1080/2162402X.2021.1936757, PubMed 34235003
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721
DeltaPhage--a novel helper phage for high-valence pIX phagemid display
Nucleic Acids Res, 40 (16), e120
DOI 10.1093/nar/gks341, PubMed 22539265
Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate
Rheumatol Int, 32 (5), 1271-6
DOI 10.1007/s00296-010-1765-y, PubMed 21267570
Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4
Biol Chem, 390 (2), 99-107
DOI 10.1515/BC.2009.019, PubMed 19040354
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents
Ann Rheum Dis, 68 (2), 249-52
DOI 10.1136/ard.2008.094490, PubMed 18723564
Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity
Ann Rheum Dis, 67 (3), 414-7
DOI 10.1136/ard.2007.080267, PubMed 18006540
The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation
J Biol Chem, 282 (17), 12749-54
DOI 10.1074/jbc.M611644200, PubMed 17308306
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells
Cancer Res, 62 (10), 2875-82
PubMed 12019167
Review articles
Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions
Front Oncol, 4, 378
DOI 10.3389/fonc.2014.00378, PubMed 25629004
The role of the proteasome activator PA28 in MHC class I antigen processing
Mol Immunol, 39 (3-4), 165-9
DOI 10.1016/s0161-5890(02)00099-8, PubMed 12200048
Other articles
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 69 (1), 159-161
DOI 10.1007/s00262-019-02409-6, PubMed 31776597